Suvorexant: a promising, novel treatment for insomnia
Joyce K Lee-Iannotti,1 James M Parish2 1Division of Neurology, Sleep Disorders Center, Banner University Medical Center, Phoenix, AZ, USA; 2Division of Pulmonary Medicine, Center for Sleep Medicine, Mayo Clinic, Phoenix, AZ, USA Abstract: Suvorexant a novel, orexin receptor antagonist was recently...
Saved in:
Main Authors: | Lee-Iannotti JK, Parish JM |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/f0c588f9105d42cc928f5aef83bf3bb5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
by: Norman JL, et al.
Published: (2016) -
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
by: Rosenberg R, et al.
Published: (2021) -
Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients
by: Firouzabadi N, et al.
Published: (2020) -
The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress
by: Chow M, et al.
Published: (2016) -
Brief behavioral treatment for patients with treatment-resistant insomnia
by: Wang J, et al.
Published: (2016)